<code id='695915A3EE'></code><style id='695915A3EE'></style>
    • <acronym id='695915A3EE'></acronym>
      <center id='695915A3EE'><center id='695915A3EE'><tfoot id='695915A3EE'></tfoot></center><abbr id='695915A3EE'><dir id='695915A3EE'><tfoot id='695915A3EE'></tfoot><noframes id='695915A3EE'>

    • <optgroup id='695915A3EE'><strike id='695915A3EE'><sup id='695915A3EE'></sup></strike><code id='695915A3EE'></code></optgroup>
        1. <b id='695915A3EE'><label id='695915A3EE'><select id='695915A3EE'><dt id='695915A3EE'><span id='695915A3EE'></span></dt></select></label></b><u id='695915A3EE'></u>
          <i id='695915A3EE'><strike id='695915A3EE'><tt id='695915A3EE'><pre id='695915A3EE'></pre></tt></strike></i>

          
          WSS
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          knowledge